Redwood City, California, United States · Remote OK
$65/hr–$110/hr
Adverum Biotechnologies, wholly owned subsidiary of Eli Lilly and Company, is looking for an Associate Director, Scientific & Medical Affairs (Contract) to join our team. This role will be responsible for scientific comm…
Skills: Scientific communication, Medical affairs, Clinical trial data analysis, Publication planning, Medical writing
Redwood City, California, United States · Remote OK
$75/hr–$130/hr
Adverum Biotechnologies, wholly owned subsidiary of Eli Lilly and Company, is looking for a Director, HEOR (Contract) to join our team. The Director, HEOR leads the development and execution of evidence generation strate…
Skills: HEOR strategy, Evidence generation, Ophthalmology, Retina, Clinical development
Redwood City, California, United States · Hybrid
Adverum Biotechnologies, Inc., a wholly owned subsidiary of Eli Lilly and Company is a mission-driven clinical-stage company that aims to establish gene therapy as a new standard of care for highly prevalent ocular disea…
Skills: Quality Systems Optimization, CMC, GMP Compliance, Regulatory Requirements, Risk Management
Redwood City, California, United States • Remote OK
Sign up with Clera and we'll reach out the moment a role actually fits you — no more spraying applications into the void.
The Associate Director will lead scientific communication and medical affairs activities, including the development of publication plans and clinical data interpretation. They will also serve as a scientific expert, collaborating with cross-functional teams and external stakeholders to support clinical trial and launch initiatives.
Candidates must hold a terminal degree such as a PharmD, PhD, or MD and possess 5-7 years of industry experience. Proficiency in ophthalmology or gene therapy, along with strong publication experience and communication skills, is highly desired.
Adverum Biotechnologies, wholly owned subsidiary of Eli Lilly and Company, is looking for an Associate Director, Scientific & Medical Affairs (Contract) to join our team. This role will be responsible for scientific communication and medical affairs activities including clinical trial, pre-launch and launch.
All recruiters and agency inquiries must go through the Adverum internal Talent Team. Unsolicited resumes sent to Adverum will be considered Adverum's property. Adverum’s Talent Acquisition team must expressly engage agencies for any requisition.
\nWhat you'll do:This contract role will be managed and payrolled through one of our preferred vendors, who will be your employer of record for the duration of the assignment. The hourly range for this position is between $65.00 USD to $110.00 USD per hour. This hourly range is an estimate, and the actual hourly rate may vary based on a candidate’s qualifications, including education, length of experience, location, and market data. The vendor will provide compensation and benefit options in accordance with specific state requirements, including paid sick leave accrual.
As a team member of Adverum Biotechnologies, a wholly owned subsidiary of Eli Lilly, during your assignment, you'll work alongside our Medical Affairs team and broader cross-functional teams, and the opportunity to contribute to meaningful work within gene therapy, ophthalmology care.
We are on a global mission to establish gene therapy as a new standard of care for the leading causes of vision loss.
Adverum Biotechnologies (NASDAQ: ADVM) is a clinical-stage company that aims to establish gene therapy as a new standard of care for highly prevalent ocular diseases with the aspiration of developing functional cures to restore vision and prevent blindness. Leveraging the research capabilities of its proprietary, intravitreal (IVT) platform, Adverum is developing durable, single-administration therapies, designed to be delivered in physicians’ offices, to eliminate the need for frequent ocular injections to treat these diseases. Adverum is evaluating its novel gene therapy candidate, ixoberogene soroparvovec (Ixo-vec, formerly referred to as ADVM-022), as a one-time, IVT injection for patients with neovascular or wet age-related macular degeneration. By overcoming the challenges associated with current treatment paradigms for these debilitating ocular diseases, Adverum aspires to transform the standard of care, preserve vision, and create a profound societal impact around the globe. A wholly-owned subsidiary of Eli Lilly and Company.
Offices: 100 Cardinal Way, Redwood City, California 94063, US
We are on a global mission to establish gene therapy as a new standard of care for the leading causes of vision loss.
Adverum Biotechnologies (NASDAQ: ADVM) is a clinical-stage company that aims to establish gene therapy as a new standard of care for highly prevalent ocular diseases with the aspiration of developing functional cures to restore vision and prevent blindness. Leveraging the research capabilities of its proprietary, intravitreal (IVT) platform, Adverum is developing durable, single-administration therapies, designed to be delivered in physicians’ offices, to eliminate the need for frequent ocular injections to treat these diseases. Adverum is evaluating its novel gene therapy candidate, ixoberogene soroparvovec (Ixo-vec, formerly referred to as ADVM-022), as a one-time, IVT injection for patients with neovascular or wet age-related macular degeneration. By overcoming the challenges associated with current treatment paradigms for these debilitating ocular diseases, Adverum aspires to transform the standard of care, preserve vision, and create a profound societal impact around the globe. A wholly-owned subsidiary of Eli Lilly and Company.
Offices: 100 Cardinal Way, Redwood City, California 94063, US
